Curie Capital
Curie Capital is a life science-focused venture capital firm established in 2018 and headquartered in Amsterdam, Netherlands. The firm aims to invest in early-stage companies within the biotechnology, pharmaceutical, and medical technology sectors, with particular emphasis on therapeutics, diagnostics, and medical devices. Founded by Mariette van der Velden and Han de Groot, both of whom possess extensive experience in investing and entrepreneurship, Curie Capital combines their complementary skills and networks to support the development of talented teams and innovative science and technology. The firm seeks to foster the growth of its portfolio companies from inception through to potential public exit.
TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Developer of tumor localization technology designed to improve care for cancer patients. The company's technology uses a tiny implanted magnetic seed to precisely mark the tumor and a detection probe to accurately locate the seed during surgery, enabling patients to receive affordable cancerous tumor surgery and improved surgical care.
TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Developer of tumor localization technology designed to improve care for cancer patients. The company's technology uses a tiny implanted magnetic seed to precisely mark the tumor and a detection probe to accurately locate the seed during surgery, enabling patients to receive affordable cancerous tumor surgery and improved surgical care.
Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.
Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.